Valneva initiates phase 1 trial of second-generation zika vaccine candidate

Saint-herblain (france), march 26, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced the initiation of a phase 1 clinical trial to investigate the
VALN Ratings Summary
VALN Quant Ranking